My watch list
my.bionity.com  
Login  

Malaria drug combo could help prevent pregnancy complications

24-Jan-2014

An anti-malaria drug combination might be useful in helping to prevent pregnancy complications in women with lupus and the related disorder antiphospholipid syndrome, Yale School of Medicine researchers have found in a new study published in the American Journal of Reproductive Immunology.

Circulating antibodies called antiphospholipid antibodies are normally produced by the body to recognize and attack bacteria and other microbe. In those with lupus and/or antiphospholipid syndrome, however, these antibodies recognize and attack the body's own proteins, putting women at high risk for recurrent pregnancy loss and late gestational complications, such as preeclampsia.

Patients with lupus or antiphospholipid syndrome are often treated with the anti-malarial drug hydroxychloroquine. While the drug can be safely continued during pregnancy, it was unknown whether it might be beneficial in preventing pregnancy complications in women with lupus and/or antiphospholipid syndrome.

In this new study, senior author Vikki M. Abrahams, associate professor in the Department of Obstetrics, Gynecology & Reproductive Sciences at Yale, and first author and Yale medical student Caroline Albert explored whether the drug could treat obstetrical antiphospholipid syndrome.

Abrahams and Albert used a lab-based system to measure the detrimental effects of antiphospholipid antibodies on human placental trophoblast cell function.

"We found that hydroxychloroquine partially reversed some, but not all, of the detrimental effects of antiphospholipid antibodies on human placental cell function," said Abrahams. "So perhaps some form of combination therapy that includes hydroxychloroquine may be beneficial to pregnant patients with lupus and/or antiphospholipid syndrome."

Facts, background information, dossiers
More about Yale University
  • News

    CureVac Enters into an Exclusive Collaborative Research Agreement with Yale University

    CureVac AG announced it has entered into a Collaborative Research Agreement (“CRA”) with Yale University for discovery research into mRNA-based pulmonary therapeutic candidates.  The exclusive CRA covers the development of an undisclosed number of novel mRNA-based candidates for pulmonary d ... more

    How fatal biofilms form

    By severely curtailing the effects of antibiotics, the formation of organized communities of bacterial cells known as biofilms can be deadly during surgeries and in urinary tract infections. Yale researchers have just come a lot closer to understanding how these biofilms develop, and potent ... more

    Seeing how cells work as never before

    Yale is adding microscopy that provides an unprecedented view of specimens whose thickness had thwarted close inspection Biological structures exist and function in three dimensions, but the limitations of imaging technology have long meant that scientists could examine only two dimensions ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE